149 related articles for article (PubMed ID: 31492820)
1. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
Mottini C; Tomihara H; Carrella D; Lamolinara A; Iezzi M; Huang JK; Amoreo CA; Buglioni S; Manni I; Robinson FS; Minelli R; Kang Y; Fleming JB; Kim MP; Bristow CA; Trisciuoglio D; Iuliano A; Del Bufalo D; Di Bernardo D; Melisi D; Draetta GF; Ciliberto G; Carugo A; Cardone L
Cancer Res; 2019 Nov; 79(21):5612-5625. PubMed ID: 31492820
[TBL] [Abstract][Full Text] [Related]
2. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
4. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
6. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
Brown WS; McDonald PC; Nemirovsky O; Awrey S; Chafe SC; Schaeffer DF; Li J; Renouf DJ; Stanger BZ; Dedhar S
Cell Rep Med; 2020 Nov; 1(8):100131. PubMed ID: 33294856
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
9. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
10. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
11. Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
[TBL] [Abstract][Full Text] [Related]
12. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
16. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract][Full Text] [Related]
18. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.
Chen PY; Muzumdar MD; Dorans KJ; Robbins R; Bhutkar A; Del Rosario A; Mertins P; Qiao J; Schafer AC; Gertler F; Carr S; Jacks T
Cancer Res; 2018 Feb; 78(4):985-1002. PubMed ID: 29279356
[TBL] [Abstract][Full Text] [Related]
19. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.
Cruz VH; Arner EN; Du W; Bremauntz AE; Brekken RA
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938713
[TBL] [Abstract][Full Text] [Related]
20. The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
Cayron C; Guillermet-Guibert J
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101473. PubMed ID: 32593694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
